Compare Ally Financial Inc (ALLY) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ally Financial Inc vs Incyte Corporation — how do they compare? Ally Financial Inc trades at $44.15 (market cap $13.37B), while Incyte Corporation trades at $120.61 (market cap $24.54B). The key difference: Incyte Corporation is the larger of the two by market cap, and Ally Financial Inc pays a 2.73% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| ALLY | INCY | |
|---|---|---|
Market Cap | $13.37B | $24.54B |
Sector | Financials | Health |
52-Week High | $47.25 | $129.93 |
52-Week Low | $35.96 | $81.61 |
Dividend Yield | 2.73% | — |
Enterprise Value | — | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ally Financial (ALLY) trades at $43.79, showing modest daily gains of 0.16%. The stock presents a compelling valuation with a P/E of 10.34 and P/B of 0.99, trading below analyst consensus target of $54.40. Recent Q2 2026 earnings missed expectations despite revenue growth, while technical indicators show bearish momentum with the stock trading near key support levels. The company maintains strong institutional support with 68% analyst buy ratings and recently declared a $0.30 dividend.
Ally offers value investment potential with attractive valuation metrics and solid dividend yield, though near-term headwinds include recent earnings miss and bearish technical signals. The auto finance business faces credit risk concerns amid economic uncertainty, but long-term digital banking leadership and improving margins provide growth catalysts. Upside potential exists if the company can maintain credit quality while expanding its digital banking footprint.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
